search
Back to results

A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Semaglutide
Placebo (semaglutide)
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female, age above or equal to 50 years at the time of signing informed consent
  • Body mass index equal to or less than 39.9 kg/m^2
  • Diagnosed with type 2 diabetes 180 daysor more prior to the day of the first screening visit
  • HbA1c 6.0% - 9.0% (42-75 mmol/mol) (both inclusive)
  • Established cardiovascular disease

Exclusion Criteria:

  • Hospitalisation for unstable angina pectoris or transient ischaemic attack within 90 days prior to the day of the first screening visit.
  • Planned coronary, carotid or peripheral artery revascularisation.
  • Presently classified as being in New York Heart Association (NYHA) equal to or above Class III.
  • Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or systemic anti-inflammatory drugs within 90 days prior to the first screening visit. Stable treatment with acetylsalicylic acid for prevention of cardiovascular events and occasional use of propionic acid derivatives drugs (e.g. ibuprofen) is allowed.

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Semaglutide

Placebo

Arm Description

Semaglutide injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg semaglutide is reached.

Placebo injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg placebo is reached.

Outcomes

Primary Outcome Measures

Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries
Ratio

Secondary Outcome Measures

Change in maximum target-to-background ratio (TBR) for 68Ga-DOTATATE in the carotid arteries
Ratio
Change in total wall volume of the most diseased carotid artery
mm3
Change in lipid rich necrotic core (LRNC) volume of the atherosclerotic plaque in the most diseased carotid artery
mm3
Change in average fibrous cap thickness (FCT) of the atherosclerotic plaque in the most diseased carotid artery
mm

Full Information

First Posted
July 22, 2019
Last Updated
August 7, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT04032197
Brief Title
A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes
Official Title
A Trial Investigating the Effect of Semaglutide on Atherosclerosis in Patients With Cardiovascular Disease and Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
August 12, 2019 (Actual)
Primary Completion Date
December 16, 2022 (Actual)
Study Completion Date
June 6, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study looks into how the type 2 diabetes medicine, semaglutide, can prevent risk of heart disease complications and stroke. Participants will either get semaglutide or placebo ("dummy" medicine) - which treatment is decided by chance. Semaglutide is a new medicine to treat type 2 diabetes and can be prescribed by doctors in some countries. The study medicine will be in a pen, and must be injected with a needle in the stomach, thigh or upper arm once a week. The study will last for 57-63 weeks. Participants will have 10 clinic visits with the study doctor, 5 visits to the specialised clinic for imaging and at least 1 phone contact. Participants' health will be monitored carefully and blood samples will therefore be taken at the clinic visits. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Sponsor staff involved in the clinical trial is masked according to company standard procedures
Allocation
Randomized
Enrollment
101 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Semaglutide
Arm Type
Experimental
Arm Description
Semaglutide injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg semaglutide is reached.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg placebo is reached.
Intervention Type
Drug
Intervention Name(s)
Semaglutide
Intervention Description
Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
Intervention Type
Drug
Intervention Name(s)
Placebo (semaglutide)
Intervention Description
Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
Primary Outcome Measure Information:
Title
Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries
Description
Ratio
Time Frame
From baseline (from 41 days before randomisation) to week 26
Secondary Outcome Measure Information:
Title
Change in maximum target-to-background ratio (TBR) for 68Ga-DOTATATE in the carotid arteries
Description
Ratio
Time Frame
From baseline (from 40 days before randomisation) to week 26
Title
Change in total wall volume of the most diseased carotid artery
Description
mm3
Time Frame
From baseline (from 41 days before randomisation) to week 52
Title
Change in lipid rich necrotic core (LRNC) volume of the atherosclerotic plaque in the most diseased carotid artery
Description
mm3
Time Frame
From baseline (from 41 days before randomisation) to week 52
Title
Change in average fibrous cap thickness (FCT) of the atherosclerotic plaque in the most diseased carotid artery
Description
mm
Time Frame
From baseline (from 41 days before randomisation) to week 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, age above or equal to 50 years at the time of signing informed consent Body mass index equal to or less than 39.9 kg/m^2 Diagnosed with type 2 diabetes 180 daysor more prior to the day of the first screening visit HbA1c 6.0% - 9.0% (42-75 mmol/mol) (both inclusive) Established cardiovascular disease Exclusion Criteria: Hospitalisation for unstable angina pectoris or transient ischaemic attack within 90 days prior to the day of the first screening visit Planned coronary, carotid or peripheral artery revascularisation. Presently classified as being in New York Heart Association (NYHA) equal to or above Class III Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or systemic anti-inflammatory drugs within 90 days prior to the first screening visit. Stable treatment with acetylsalicylic acid for prevention of cardiovascular events and occasional use of propionic acid derivatives drugs (e.g. ibuprofen) is allowed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Reporting Anchor and Disclosure (1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Graz
ZIP/Postal Code
8010
Country
Austria
Facility Name
Novo Nordisk Investigational Site
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Facility Name
Novo Nordisk Investigational Site
City
Stockholm
ZIP/Postal Code
171 76
Country
Sweden
Facility Name
Novo Nordisk Investigational Site
City
Uppsala
ZIP/Postal Code
75237
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes

We'll reach out to this number within 24 hrs